Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Nanobody Market Research Report Information by Type (Mono-Specific, and Multi-Specific) by Application [Therapeutic (Cancer, Neurodegenerative Diseases, Infectious Diseases, and Others), Diagnostic (Detection Of Proteins and Microorganisms, Detection Of Small Molecules, and Imaging), Research] , by End User (Pharmaceutical & Biotechnology Companies, Research Laboratories, and Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032


ID: MRFR/HC/9539-CR | 128 Pages | Author: Rahul Gotadki| August 2023

Nanobody Market Segmentation


Nanobody Type Outlook (USD Billion, 2019-2032)



  • Mono-Specific

  • Multi-Specific


Nanobody Application Outlook (USD Billion, 2019-2032)



  • Therapeutic

    • Cancer

    • Neurodegenerative Diseases

    • Infectious Diseases

    • Others



  • Diagnostic

    • Detection Of Proteins and Microorganisms

    • Detection Of Small Molecules

    • Imaging



  • Research


Nanobody End User Outlook (USD Billion, 2019-2032)



  • Pharmaceutical & Biotechnology Companies

  • Research Laboratories

  • Others


Nanobody Regional Outlook (USD Billion, 2019-2032)




  • North America Outlook (USD Billion, 2019-2032)


    • North America Nanobody by Type

      • Mono-Specific

      • Multi-Specific




    • North America Nanobody by Application

      • Therapeutic

        • Cancer

        • Neurodegenerative Diseases

        • Infectious Diseases

        • Others



      • Diagnostic

        • Detection Of Proteins and Microorganisms

        • Detection Of Small Molecules

        • Imaging



      • Research




    • North America Nanobody by End User

      • Pharmaceutical & Biotechnology Companies

      • Research Laboratories

      • Others



    • US Outlook (USD Billion, 2019-2032)


    • US Nanobody by Type

      • Mono-Specific

      • Multi-Specific




    • US Nanobody by Application

      • Therapeutic

        • Cancer

        • Neurodegenerative Diseases

        • Infectious Diseases

        • Others



      • Diagnostic

        • Detection Of Proteins and Microorganisms

        • Detection Of Small Molecules

        • Imaging



      • Research




    • US Nanobody by End User

      • Pharmaceutical & Biotechnology Companies

      • Research Laboratories

      • Others



    • Canada Outlook (USD Billion, 2019-2032)


    • Canada Nanobody by Type

      • Mono-Specific

      • Multi-Specific




    • Canada Nanobody by Application

      • Therapeutic

        • Cancer

        • Neurodegenerative Diseases

        • Infectious Diseases

        • Others



      • Diagnostic

        • Detection Of Proteins and Microorganisms

        • Detection Of Small Molecules

        • Imaging



      • Research




    • Canada Nanobody by End User

      • Pharmaceutical & Biotechnology Companies

      • Research Laboratories

      • Others




    • Europe Outlook (USD Billion, 2019-2032)


      • Europe Nanobody by Type

        • Mono-Specific

        • Multi-Specific




      • Europe Nanobody by Application

        • Therapeutic

          • Cancer

          • Neurodegenerative Diseases

          • Infectious Diseases

          • Others



        • Diagnostic

          • Detection Of Proteins and Microorganisms

          • Detection Of Small Molecules

          • Imaging



        • Research




      • Europe Nanobody by End User

        • Pharmaceutical & Biotechnology Companies

        • Research Laboratories

        • Others




      • Germany Outlook (USD Billion, 2019-2032)


      • Germany Nanobody by Type

        • Mono-Specific

        • Multi-Specific




      • Germany Nanobody by Application

        • Therapeutic

          • Cancer

          • Neurodegenerative Diseases

          • Infectious Diseases

          • Others



        • Diagnostic

          • Detection Of Proteins and Microorganisms

          • Detection Of Small Molecules

          • Imaging



        • Research




      • Germany Nanobody by End User

        • Pharmaceutical & Biotechnology Companies

        • Research Laboratories

        • Others



      • France Outlook (USD Billion, 2019-2032)


      • France Nanobody by Type

        • Mono-Specific

        • Multi-Specific




      • France Nanobody by Application

        • Therapeutic

          • Cancer

          • Neurodegenerative Diseases

          • Infectious Diseases

          • Others



        • Diagnostic

          • Detection Of Proteins and Microorganisms

          • Detection Of Small Molecules

          • Imaging



        • Research




      • France Nanobody by End User

        • Pharmaceutical & Biotechnology Companies

        • Research Laboratories

        • Others



      • UK Outlook (USD Billion, 2019-2032)


      • UK Nanobody by Type

        • Mono-Specific

        • Multi-Specific




      • UK Nanobody by Application

        • Therapeutic

          • Cancer

          • Neurodegenerative Diseases

          • Infectious Diseases

          • Others



        • Diagnostic

          • Detection Of Proteins and Microorganisms

          • Detection Of Small Molecules

          • Imaging



        • Research




      • UK Nanobody by End User

        • Pharmaceutical & Biotechnology Companies

        • Research Laboratories

        • Others



      • Italy Outlook (USD Billion, 2019-2032)


      • Italy Nanobody by Type

        • Mono-Specific

        • Multi-Specific




      • Italy Nanobody by Application

        • Therapeutic

          • Cancer

          • Neurodegenerative Diseases

          • Infectious Diseases

          • Others



        • Diagnostic

          • Detection Of Proteins and Microorganisms

          • Detection Of Small Molecules

          • Imaging



        • Research




      • Italy Nanobody by End User

        • Pharmaceutical & Biotechnology Companies

        • Research Laboratories

        • Others



      • Spain Outlook (USD Billion, 2019-2032)


      • Spain Nanobody by Type

        • Mono-Specific

        • Multi-Specific




      • Spain Nanobody by Application

        • Therapeutic

          • Cancer

          • Neurodegenerative Diseases

          • Infectious Diseases

          • Others



        • Diagnostic

          • Detection Of Proteins and Microorganisms

          • Detection Of Small Molecules

          • Imaging



        • Research




      • Spain Nanobody by End User

        • Pharmaceutical & Biotechnology Companies

        • Research Laboratories

        • Others



      • Rest Of Europe Outlook (USD Billion, 2019-2032)


      • Rest of Europe Nanobody by Type

        • Mono-Specific

        • Multi-Specific




      • Rest of Europe Nanobody by Application

        • Therapeutic

          • Cancer

          • Neurodegenerative Diseases

          • Infectious Diseases

          • Others



        • Diagnostic

          • Detection Of Proteins and Microorganisms

          • Detection Of Small Molecules

          • Imaging



        • Research




      • Rest of Europe Nanobody by End User

        • Pharmaceutical & Biotechnology Companies

        • Research Laboratories

        • Others




      • Asia-Pacific Outlook (USD Billion, 2019-2032)


        • Asia-Pacific Nanobody by Type

          • Mono-Specific

          • Multi-Specific




        • Asia-Pacific Nanobody by Application

          • Therapeutic

            • Cancer

            • Neurodegenerative Diseases

            • Infectious Diseases

            • Others



          • Diagnostic

            • Detection Of Proteins and Microorganisms

            • Detection Of Small Molecules

            • Imaging



          • Research




        • Asia-Pacific Nanobody by End User

          • Pharmaceutical & Biotechnology Companies

          • Research Laboratories

          • Others




        • China Outlook (USD Billion, 2019-2032)


        • China Nanobody by Type

          • Mono-Specific

          • Multi-Specific




        • China Nanobody by Application

          • Therapeutic

            • Cancer

            • Neurodegenerative Diseases

            • Infectious Diseases

            • Others



          • Diagnostic

            • Detection Of Proteins and Microorganisms

            • Detection Of Small Molecules

            • Imaging



          • Research




        • China Nanobody by End User

          • Pharmaceutical & Biotechnology Companies

          • Research Laboratories

          • Others




        • Japan Outlook (USD Billion, 2019-2032)


        • Japan Nanobody by Type

          • Mono-Specific

          • Multi-Specific




        • Japan Nanobody by Application

          • Therapeutic

            • Cancer

            • Neurodegenerative Diseases

            • Infectious Diseases

            • Others



          • Diagnostic

            • Detection Of Proteins and Microorganisms

            • Detection Of Small Molecules

            • Imaging



          • Research




        • Japan Nanobody by End User

          • Pharmaceutical & Biotechnology Companies

          • Research Laboratories

          • Others




        • India Outlook (USD Billion, 2019-2032)


        • India Nanobody by Type

          • Mono-Specific

          • Multi-Specific




        • India Nanobody by Application

          • Therapeutic

            • Cancer

            • Neurodegenerative Diseases

            • Infectious Diseases

            • Others



          • Diagnostic

            • Detection Of Proteins and Microorganisms

            • Detection Of Small Molecules

            • Imaging



          • Research




        • India Nanobody by End User

          • Pharmaceutical & Biotechnology Companies

          • Research Laboratories

          • Others




        • Australia Outlook (USD Billion, 2019-2032)


        • Australia Nanobody by Type

          • Mono-Specific

          • Multi-Specific




        • Australia Nanobody by Application

          • Therapeutic

            • Cancer

            • Neurodegenerative Diseases

            • Infectious Diseases

            • Others



          • Diagnostic

            • Detection Of Proteins and Microorganisms

            • Detection Of Small Molecules

            • Imaging



          • Research




        • Australia Nanobody by End User

          • Pharmaceutical & Biotechnology Companies

          • Research Laboratories

          • Others




        • South Korea Outlook (USD Billion, 2019-2032)


        • South Korea Nanobody by Type

          • Mono-Specific

          • Multi-Specific




        • South Korea Nanobody by Application

          • Therapeutic

            • Cancer

            • Neurodegenerative Diseases

            • Infectious Diseases

            • Others



          • Diagnostic

            • Detection Of Proteins and Microorganisms

            • Detection Of Small Molecules

            • Imaging



          • Research




        • South Korea Nanobody by End User

          • Pharmaceutical & Biotechnology Companies

          • Research Laboratories

          • Others




        • Rest of Asia-Pacific Outlook (USD Billion, 2019-2032)


        • Rest of Asia-Pacific Nanobody by Type

          • Mono-Specific

          • Multi-Specific




        • Rest of Asia-Pacific Nanobody by Application

          • Therapeutic

            • Cancer

            • Neurodegenerative Diseases

            • Infectious Diseases

            • Others



          • Diagnostic

            • Detection Of Proteins and Microorganisms

            • Detection Of Small Molecules

            • Imaging



          • Research




        • Rest of Asia-Pacific Nanobody by End User

          • Pharmaceutical & Biotechnology Companies

          • Research Laboratories

          • Others




        • Rest of the World Outlook (USD Billion, 2019-2032)


          • Rest of the World Nanobody by Type

            • Mono-Specific

            • Multi-Specific




          • Rest of the World Nanobody by Application

            • Therapeutic

              • Cancer

              • Neurodegenerative Diseases

              • Infectious Diseases

              • Others



            • Diagnostic

              • Detection Of Proteins and Microorganisms

              • Detection Of Small Molecules

              • Imaging



            • Research




          • Rest of the World Nanobody by End User

            • Pharmaceutical & Biotechnology Companies

            • Research Laboratories

            • Others




          • Middle East Outlook (USD Billion, 2019-2032)


          • Middle East Nanobody by Type

            • Mono-Specific

            • Multi-Specific




          • Middle East Nanobody by Application

            • Therapeutic

              • Cancer

              • Neurodegenerative Diseases

              • Infectious Diseases

              • Others



            • Diagnostic

              • Detection Of Proteins and Microorganisms

              • Detection Of Small Molecules

              • Imaging



            • Research




          • Middle East Nanobody by End User

            • Pharmaceutical & Biotechnology Companies

            • Research Laboratories

            • Others




          • Africa Outlook (USD Billion, 2019-2032)


          • Africa Nanobody by Type

            • Mono-Specific

            • Multi-Specific




          • Africa Nanobody by Application

            • Therapeutic

              • Cancer

              • Neurodegenerative Diseases

              • Infectious Diseases

              • Others



            • Diagnostic

              • Detection Of Proteins and Microorganisms

              • Detection Of Small Molecules

              • Imaging



            • Research




          • Africa Nanobody by End User

            • Pharmaceutical & Biotechnology Companies

            • Research Laboratories

            • Others




          • Latin America Outlook (USD Billion, 2019-2032)


          • Latin America Nanobody by Type

            • Mono-Specific

            • Multi-Specific




          • Latin America Nanobody by Application

            • Therapeutic

              • Cancer

              • Neurodegenerative Diseases

              • Infectious Diseases

              • Others



            • Diagnostic

              • Detection Of Proteins and Microorganisms

              • Detection Of Small Molecules

              • Imaging



            • Research




          • Latin America Nanobody by End User

            • Pharmaceutical & Biotechnology Companies

            • Research Laboratories

            • Others











Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.4 FORECASTING TECHNIQUES

3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.5.1 BOTTOM-UP APPROACH

3.5.2 TOP-DOWN APPROACH

3.6 DATA TRIANGULATION

3.7 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES

4.2.2 RISING DEMAND FOR PRECISION MEDICINE

4.2.3 INCREASING INVESTMENT IN NANOBODY RESEARCH AND DEVELOPMENT

4.3 RESTRAINTS

4.3.1 MANUFACTURING CHALLENGES AND HIGH PRODUCTION COSTS

4.4 OPPORTUNITY

4.4.1 GROWING DEVELOPMENT OF NEW APPLICATIONS OF NANOBODIES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL NANOBODY MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON CLINICAL TRIALS

5.3.3 IMPACT ON DEMAND AND SUPPLY

6 GLOBAL NANOBODY MARKET, BY TYPE

6.1 OVERVIEW

6.2 MONO-SPECIFIC

6.3 MULTI-SPECIFIC

7 GLOBAL NANOBODY MARKET, BY APPLICATION

7.1 OVERVIEW

7.2 THERAPEUTIC

7.2.1 CANCER

7.2.2 NEURODEGENERATIVE DISEASES

7.2.3 INFECTIOUS DISEASES

7.2.4 OTHERS

7.3 DIAGNOSTIC

7.3.1 DETECTION OF PROTEINS AND MICROORGANISMS

7.3.2 DETECTION OF SMALL MOLECULES

7.3.3 IMAGING

7.4 RESEARCH

8 GLOBAL NANOBODY MARKET, BY END USER

8.1 OVERVIEW

8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

8.3 RESEARCH LABORATORIES

8.4 OTHERS

9 GLOBAL NANOBODY MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 UK

9.3.3 FRANCE

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA PACIFIC

9.4.1 JAPAN

9.4.2 CHINA

9.4.3 INDIA

9.4.4 SOUTH KOREA

9.4.5 AUSTRALIA

9.4.6 REST OF ASIA PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL NANOBODY MARKET

10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL NANOBODY MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL

10.6.2 MERGER/ ACQUISITION

10.6.3 PARTNERSHIP/ AGREEMENT/COLLABORATION

10.7 MAJOR PLAYERS SALES ANALYSIS

10.8 MAJOR PLAYERS R&D ANALYSIS

11 COMPANY PROFILES

11.1 SANOFI

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 MERCK KGAA

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 BIOCYTOGEN

11.3.1 COMPANY OVERVIEWS

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 KEY STRATEGIES

11.4 PROTEINTECH GROUP, INC.

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 KEY STRATEGIES

11.5 NOVARTIS AG

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTSS

11.5.5 SWOT ANALYSIS

11.5.6 KEY STRATEGIES

11.6 GENSCRIPT

11.6.1 COMPANY OVERVIEWS

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 SENSEI BIOTHERAPEUTICS, INC

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGIES

11.8 BERONI GROUP

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 KEY STRATEGIES

11.9 EXEVIR BIO

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 KEY STRATEGIES

11.10 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 KEY STRATEGIES

11.11 DIOSCURE THERAPEUTICS SE

11.11.1 COMPANY OVERVIEW

11.11.2 FINANCIAL OVERVIEW

11.11.3 PRODUCTS OFFERED

11.11.4 KEY DEVELOPMENTS

11.11.5 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 GLOBAL NANOBDOY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 3 GLOBAL NANOBDOY MARKET, FOR MONO-SPECIFIC, BY REGION, 2019–2032 (USD BILLION)

TABLE 4 GLOBAL NANOBDOY MARKET, FOR MULTI-SPECIFIC, BY REGION, 2019–2032 (USD BILLION)

TABLE 5 GLOBAL NANOBDOY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 6 GLOBAL NANOBDOY MARKET, FOR THERAPEUTIC, BY REGION, 2019–2032 (USD BILLION)

TABLE 7 GLOBAL NANOBDOY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 8 GLOBAL NANOBDOY MARKET, FOR CANCER, BY REGION, 2019–2032 (USD BILLION)

TABLE 9 GLOBAL NANOBDOY MARKET, FOR NEURODEGENERATIVE DISEASES, BY REGION, 2019–2032 (USD BILLION)

TABLE 10 GLOBAL NANOBDOY MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2019–2032 (USD BILLION)

TABLE 11 GLOBAL NANOBDOY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD BILLION)

TABLE 12 GLOBAL NANOBDOY MARKET, FOR DIAGNOSTIC, BY REGION, 2019–2032 (USD BILLION)

TABLE 13 GLOBAL NANOBDOY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 14 GLOBAL NANOBDOY MARKET, FOR DETECTION OF PROTEINS AND MICROORGANISMS, BY REGION, 2019–2032 (USD BILLION)

TABLE 15 GLOBAL NANOBDOY MARKET, FOR DETECTION OF SMALL MOLECULES, BY REGION, 2019–2032 (USD BILLION)

TABLE 16 GLOBAL NANOBDOY MARKET, FOR IMAGING, BY REGION, 2019–2032 (USD BILLION)

TABLE 17 GLOBAL NANOBDOY MARKET, FOR RESEARCH, BY REGION, 2019–2032 (USD BILLION)

TABLE 18 GLOBAL NANOBDOY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 19 GLOBAL NANOBDOY MARKET, FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2032 (USD BILLION)

TABLE 20 GLOBAL NANOBDOY MARKET, FOR RESEARCH LABORATORIES, BY REGION, 2019–2032 (USD BILLION)

TABLE 21 GLOBAL NANOBDOY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD BILLION)

TABLE 22 GLOBAL: NANOBODY MARKET, BY REGION, 2019–2032 (USD BILLION)

TABLE 23 NORTH AMERICA: NANOBODY MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 24 NORTH AMERICA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 25 NORTH AMERICA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 26 NORTH AMERICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 27 NORTH AMERICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 28 NORTH AMERICA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 29 US: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 30 US: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 31 US: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 32 US: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 33 US: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 34 CANADA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 35 CANADA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 36 CANADA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 37 CANADA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 38 CANADA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 39 EUROPE: NANOBODY MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 40 EUROPE: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 41 EUROPE: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 42 EUROPE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 43 EUROPE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 44 EUROPE: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 45 GERMANY: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 46 GERMANY: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 47 GERMANY: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 48 GERMANY: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 49 GERMANY: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 50 UK: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 51 UK: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 52 UK: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 53 UK: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 54 UK: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 55 FRANCE: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 56 FRANCE: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 57 FRANCE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 58 FRANCE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 59 FRANCE: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 60 ITALY: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 61 ITALY: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 62 ITALY: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 63 ITALY: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 64 ITALY: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 65 SPAIN: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 66 SPAIN: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 67 SPAIN: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 68 SPAIN: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 69 SPAIN: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 70 REST OF EUROPE: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 71 REST OF EUROPE: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 72 REST OF EUROPE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 73 REST OF EUROPE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 74 REST OF EUROPE: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 75 ASIA PACIFIC: NANOBODY MARKET, BY COUNTRY, 2019-2032 (USD BILLION)

TABLE 76 ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 77 ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 78 ASIA-PACIFIC: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 79 ASIA-PACIFIC: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 80 ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 81 JAPAN: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 82 JAPAN: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 83 JAPAN: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 84 JAPAN: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 85 JAPAN: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 86 CHINA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 87 CHINA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 88 CHINA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 89 CHINA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 90 CHINA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 91 INDIA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 92 INDIA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 93 INDIA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 94 INDIA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 95 INDIA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 96 SOUTH KOREA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 97 SOUTH KOREA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 98 SOUTH KOREA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 99 SOUTH KOREA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 100 SOUTH KOREA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 101 AUSTRALIA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 102 AUSTRALIA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 103 AUSTRALIA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 104 AUSTRALIA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 105 AUSTRALIA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 106 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 107 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 108 REST OF ASIA-PACIFIC: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 109 REST OF ASIA-PACIFIC: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 110 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 111 REST OF THE WORLD: NANOBODY MARKET, BY REGION, 2019-2032(USD BILLION)

TABLE 112 REST OF THE WORLD: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 113 REST OF THE WORLD: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 114 REST OF THE WORLD: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 115 REST OF THE WORLD: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 116 REST OF THE WORLD: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 117 MIDDLE EAST: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 118 MIDDLE EAST: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 119 MIDDLE EAST: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 120 MIDDLE EAST: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 121 MIDDLE EAST: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 122 AFRICA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 123 AFRICA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 124 AFRICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 125 AFRICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 126 AFRICA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 127 LATIN AMERICA: NANOBODY MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 128 LATIN AMERICA: NANOBODY MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 129 LATIN AMERICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 130 LATIN AMERICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2032 (USD BILLION)

TABLE 131 LATIN AMERICA: NANOBODY MARKET, BY END USER, 2019–2032 (USD BILLION)

TABLE 132 MAJOR PLAYERS IN THE GLOBAL NANOBODY MARKET

TABLE 133 MOST ACTIVE PLAYER IN THE GLOBAL NANOBODY MARKET

TABLE 134 PRODUCT LAUNCH/PRODUCT APPROVAL

TABLE 135 MERGER/ ACQUISITION

TABLE 136 PARTNERSHIP/ AGREEMENT/COLLABORATION

TABLE 137 SANOFI: PRODUCTS OFFERED

TABLE 138 SANOFI: KEY DEVELOPMENTS

TABLE 139 MERCK KGAA: PRODUCTS OFFERED

TABLE 140 MERCK KGAA: KEY DEVELOPMENTS

TABLE 141 BIOCYTOGEN: PRODUCTS OFFERED

TABLE 142 BIOCYTOGEN: KEY DEVELOPMENTS

TABLE 143 PROTEINTECH GROUP, INC.: PRODUCTS OFFERED

TABLE 144 NOVARTIS AG: PRODUCTS OFFERED

TABLE 145 GENSCRIPT: PRODUCTS OFFERED

TABLE 146 SENSEI BIOTHERAPEUTICS: PRODUCTS OFFERED

TABLE 147 SENSEI BIOTHERAPEUTICS: KEY DEVELOPMENTS

TABLE 148 BERONI GROUP: PRODUCTS OFFERED

TABLE 149 BERONI GROUP: KEY DEVELOPMENTS

TABLE 150 EXEVIR BIO BV.: PRODUCTS OFFERED

TABLE 151 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD: PRODUCTS OFFERED

TABLE 152 DIOSCURE THERAPEUTICS SE: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL NANOBODY MARKET STRUCTURE

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: GLOBAL NANOBODY MARKET

FIGURE 5 DRIVER IMPACT ANALYSIS

FIGURE 6 RESTRAINT IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS OF THE GLOBAL NANOBODY MARKET

FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL NANOBODY MARKET

FIGURE 9 GLOBAL NANOBODY MARKET, TYPE SEGMENT ATTRACTIVENESS, (USD BILLION)

FIGURE 10 GLOBAL NANOBDOY MARKET, BY TYPE, 2022 & 2032 (USD BILLION)

FIGURE 11 GLOBAL NANOBDOY MARKET SHARE (%), BY TYPE, 2022

FIGURE 12 GLOBAL NANOBODY MARKET, APPLICATION SEGMENT ATTRACTIVENESS, (USD BILLION)

FIGURE 13 GLOBAL NANOBDOY MARKET, BY APPLICATION, 2022 & 2032 (USD BILLION)

FIGURE 14 GLOBAL NANOBDOY MARKET SHARE (%), BY APPLICATION, 2022

FIGURE 15 GLOBAL NANOBODY MARKET, END USER SEGMENT ATTRACTIVENESS, (USD BILLION)

FIGURE 16 GLOBAL NANOBDOY MARKET, BY END USER, 2022 & 2032 (USD BILLION)

FIGURE 17 GLOBAL NANOBDOY MARKET SHARE (%), BY END USER, 2022

FIGURE 18 GLOBAL: NANOBODY MARKET, BY REGION 2022 & 2032 (USD BILLION)

FIGURE 19 GLOBAL: NANOBODY MARKET SHARE (%), BY REGION, 2022

FIGURE 20 NORTH AMERICA MARKET ANALYSIS: NANOBODY MARKET, 2019-2032 (USD BILLION)

FIGURE 21 NORTH AMERICA: NANOBODY MARKET, BY COUNTRY 2022 & 2032 (USD BILLION)

FIGURE 22 NORTH AMERICA: NANOBODY MARKET SHARE (%), BY COUNTRY 2022

FIGURE 23 EUROPE MARKET ANALYSIS: NANOBODY MARKET, 2019-2032 (USD BILLION)

FIGURE 24 EUROPE: NANOBODY MARKET, BY COUNTRY 2022 & 2032 (USD BILLION)

FIGURE 25 EUROPE: NANOBODY MARKET SHARE (%), BY COUNTRY 2022

FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: NANOBODY MARKET, 2019-2032 (USD BILLION)

FIGURE 27 ASIA PACIFIC NANOBODY MARKET SHARE, BY COUNTRY 2022 & 2032 (USD BILLION)

FIGURE 28 ASIA PACIFIC: NANOBODY MARKET SHARE (%), BY COUNTRY, 2022

FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: NANOBODY MARKET, 2019-2032 (USD BILLION)

FIGURE 30 REST OF THE WORLD NANOBODY MARKET SHARE, BY REGION 2022 & 2032 (USD BILLION)

FIGURE 31 REST OF THE WORLD: NANOBODY MARKET SHARE (%), BY REGION, 2022

FIGURE 32 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 33 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL NANOBODY MARKET

FIGURE 34 GLOBAL NANOBODY MARKET: COMPETITIVE LANDSCAPE

FIGURE 35 MAJOR PLAYERS SALES, 2022 (USD BILLION)

FIGURE 36 MAJOR PLAYER R&D EXPENDITURE, 2022 (USD BILLION)

FIGURE 37 SANOFI: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 38 SANOFI: SWOT ANALYSIS

FIGURE 39 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 40 MERCK KGAA: SWOT ANALYSIS

FIGURE 41 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 42 NOVARTIS AG: SWOT ANALYSIS

FIGURE 43 GENSCRIPT: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 44 GENSCRIPT: SWOT ANALYSIS

FIGURE 45 SENSEI BIOTHERAPEUTICS: SWOT ANALYSIS

FIGURE 46 BERONI GROUP: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 47 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD: FINANCIAL OVERVIEW SNAPSHOT

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.